Skip to content

Avance clinical client news: XWPharma initiates first-in-human studies of XW10508, in development for fast-acting relief of treatment-resistant depression and chronic pain

By Gold Cross - October 20, 2021

This article is only available to ITK members and is restricted for Pharmacists. Please or Register as a Pharmacist to read the content.
Share this article:
Article tags

Articles you might be interested in

, ,

New data from ReachOut shows cost of living driving study stress, students turn online for relief

Hanna Castillo | September 18, 2024
, ,

UN seeking urgent action on superbugs

Gold Cross | September 18, 2024
,

Decades of dedication to the Australian pharmacy sector

Gold Cross | September 17, 2024
, ,

Navigating the dynamic waves of retail pharmacy

Gold Cross | September 13, 2024
SLINDA Healthcare for Women
BD Rowa automation gives you back 6 hours in your day

Latest Posts

Eating disorder experts from Australia and around the world unite in Melbourne for first-of-its-kind event
Gold Cross | September 19, 2024
The impact of mild cognitive impairment and dementia on social skills
Gold Cross | September 19, 2024
Innovation in community pharmacy—a necessity for survival and success
Gold Cross | September 19, 2024

Featured Posts

Whether forced or voluntary, change is inevitable
Gold Cross | September 18, 2024
Should we trust our guts?
Gold Cross | September 16, 2024
Navigating the dynamic waves of retail pharmacy
Gold Cross | September 13, 2024

Tags

Scroll To Top